Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

The Lancet Respiratory Medicine

Volumn 7, Issue 1, 2019, Pages 60-68

  Crestani, Bruno ^a,b,c   Huggins, John T ^d   Kaye, Mitchell ^e   Costabel, Ulrich ^f   Glaspole, Ian ^g   Ogura, Takashi ^h   Song, Jin Woo ⁱ   Stansen, Wibke ^j   Quaresma, Manuel ^j   Stowasser, Susanne ^j   Kreuter, Michael ^k,l  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e Minnesota Lung Center   (United States)

^f RUHRLANDKLINIK   (Germany)

^g MONASH UNIVERSITY   (Australia)

^h Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

ⁱ University of Ulsan College of Medicine   (South Korea)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l German Center for Lung Research ^*  (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; PLACEBO; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADVERSE EVENT; AGED; ARTICLE; BLEEDING; BRONCHITIS; CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; DISEASE EXACERBATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS;

EID: 85058783290     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30339-4     Document Type: Article

References (25)

1. Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. Kreuter, M, Swigris, J, Pittrow, D, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. Respir Res, 18, 2017, 139.
3. Fernández Pérez, ER, Daniels, CE, Schroeder, DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137 (2010), 129–137.
4. Raghu, G, Chen, SY, Yeh, WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med 2 (2014), 566–572.
5. Collard, HR, Ryerson, CJ, Corte, TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194 (2016), 265–275.
6. Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192 (2015), e3–e19.
7. Richeldi, L, Costabel, U, Selman, M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365 (2011), 1079–1087.
8. Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
9. Corte, T, Bonella, F, Crestani, B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res, 16, 2015, 116.
10. Richeldi, L, Cottin, V, Flaherty, KR, et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 108 (2014), 1023–1030.
11. Miller, MR, Hankinson, J, Brusasco, V, et al. Standardisation of spirometry. Eur Respir J 26 (2005), 319–338.
12. Collard, HR, Moore, BB, Flaherty, KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 (2007), 636–643.
13. Noth, I, Oelberg, D, Kaul, M, Conoscenti, CS, Raghu, G, Safety and tolerability of nintedanib in patients with IPF in the United States. Eur Respir J, 52, 2018, 1702106.
14. Collard, HR, Ward, AJ, Lanes, S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15 (2012), 829–835.
15. Behr, J, Kreuter, M, Hoeper, MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 46 (2015), 186–196.
16. Kreuter, M, Ehlers-Tenenbaum, S, Palmowski, K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One, 11, 2016, e0151425.
17. du Bois, RM, Weycker, D, Albera, C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184 (2011), 1382–1389.
18. Richeldi, L, Cottin, V, du Bois, RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med 113 (2016), 74–79.
19. Richeldi, L, Kreuter, M, Selman, M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 73 (2018), 581–583.
20. Ley, B, Collard, HR, King, TE Jr, Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183 (2011), 431–440.
21. Wuyts, WA, Kolb, M, Stowasser, S, Stansen, W, Huggins, JT, Raghu, G, First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung 194 (2016), 739–743.
22. Costabel, U, Inoue, Y, Richeldi, L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193 (2016), 178–185.
23. Kreuter, M, Costabel, U, Richeldi, L, et al. Statin therapy and outcomes in trials of nintedanib in idiopathic pulmonary fibrosis. Respiration 95 (2018), 317–326.
24. Raghu, G, Crestani, B, Bailes, Z, Schlenker-Herceg, R, Costabel, U, Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J, 46(suppl 59), 2015, OA4502.
25. Collard, HR, Richeldi, L, Kim, DS, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J, 49, 2017, 1601339.